A CARMIL2 gain-of-function mutation suffices to trigger most CD28 costimulatory functions in vivo
Journal of Experimental Medicine · 2025
DOI: 10.1084/jem.20250339 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2025. Verfasst von Fanghui Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Centre d'Immunologie de Marseille-Luminy (CIML), Aix Marseille Université, Institut national de la santé et de la recherche médicale (INSERM), Centre…. Hauptthemen laut MEDLINE: CD28 Antigens, CARD Signaling Adaptor Proteins, Gain of Function Mutation, Guanylate Cyclase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale.
Abstract (Originalsprache)
Naive T cell activation requires both TCR and CD28 signals. The CARMIL2 cytosolic protein enables CD28-dependent activation of the NF-κB transcription factor via its ability to link CD28 to the CARD11 adaptor protein. Here, we developed mice expressing a mutation named Carmil2QE and mimicking a mutation found in human T cell malignancies. Naive T cells from Carmil2QE mice contained preformed CARMIL2QE-CARD11 complexes in numbers comparable to those assembling in wild-type T cells after CD28 engagement. Such ready-made CARMIL2QE-CARD11 complexes also formed in CD28-deficient mice where they unexpectedly induced most of the functions that normally result from CD28 engagement in a manner that remains antigen-dependent. In turn, tumor-specific T cells expressing Carmil2QE do not require CD28 engagement and thereby escape to both PD-1 and CTLA-4 inhibition. In conclusion, we uncovered the overarching role played by CARMIL2-CARD11 signals among those triggered by CD28 and exploited them to induce potent solid tumor–specific T cell responses in the absence of CD28 ligands and immune checkpoint inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre d'Immunologie de Marseille-Luminy (CIML), Aix Marseille Université, Institut national de la santé et de la recherche médicale (INSERM), Centre national de la recherche scientifique (CNRS) , Marseille, France.
- School of Medical Technology, Xinxiang Medical University , Xinxiang City, China.
- Centre d'Immunophénomique (CIPHE), Aix Marseille Université, INSERM, CNRS , Marseille, France.
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UPS) , Toulouse, France.
- Laboratory of Mouse Genetics, Institute of Psychiatry and Neuroscience, Xinxiang Medical University , Xinxiang City, China.
- Laboratory of Immunophenomics, School of Medical Technology, Xinxiang Medical University , Xinxiang City, China.
ORCID-Profile: Fanghui Zhang, Javier Celis-Gutierrez, Lichen Zhang, Valentin Mellado, Léna Gelard, Sophie Panigot, Daiki Mori, Liaoxun Lu, Guillaume Voisinne, Carine Vilarnau Wolek, Marielle Mello, Odile Burlet-Schiltz, Anne Gonzalez de Peredo, Frédéric Fiore, Romain Roncagalli, Yinming Liang, Marie Malissen, Bernard Malissen
Förderung
- European Research Council
- Centre National de la Recherche Scientifique
- Institut National de la Santé et de la Recherche Médicale
- Agence Nationale de la Recherche
- National Natural Science Foundation of China
- Henan Province
- National Discipline Innovation and Intelligence Introduction Base 111 Project
- Investissement d'Avenir program ProFi
Zitieren
APA
Zhang, F., Celis-Gutierrez, J., Zhang, L., Mellado, V., Gelard, L., Panigot, S., Mori, D., Lu, L., Voisinne, G., Vilarnau Wolek, C., Mello, M., Burlet-Schiltz, O., Gonzalez de Peredo, A., Fiore, F., Roncagalli, R., Liang, Y., Malissen, M., & Malissen, B. (2025). A CARMIL2 gain-of-function mutation suffices to trigger most CD28 costimulatory functions in vivo. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20250339
Vancouver
Zhang F, Celis-Gutierrez J, Zhang L, Mellado V, Gelard L, Panigot S, et al. A CARMIL2 gain-of-function mutation suffices to trigger most CD28 costimulatory functions in vivo. Journal of Experimental Medicine. 2025. doi:10.1084/jem.20250339
BibTeX
@article{Zhang2025,
author = {Zhang, Fanghui and Celis-Gutierrez, Javier and Zhang, Lichen and Mellado, Valentin and Gelard, Léna and Panigot, Sophie and Mori, Daiki and Lu, Liaoxun and Voisinne, Guillaume and Vilarnau Wolek, Carine and Mello, Marielle and Burlet-Schiltz, Odile and Gonzalez de Peredo, Anne and Fiore, Frédéric and Roncagalli, Romain and Liang, Yinming and Malissen, Marie and Malissen, Bernard},
title = {A CARMIL2 gain-of-function mutation suffices to trigger most CD28 costimulatory functions in vivo},
journal = {Journal of Experimental Medicine},
year = {2025},
doi = {10.1084/jem.20250339}
}
EUVIMED